NCT02026219

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Inha University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than clopidogrel and is associated with less interindividual variability. In the PLATO trial, it was found to be superior to clopidogrel with respect to cardiovascular outcomes and total mortality without increasing the risk of bleedings. More potent and reversible receptor bindings are possible explanation for the superior outcomes. Beside the potent effect on inhibition of antiplatelet function, ticagrelor has previously been demonstrated to increase adenosine levels by inhibiting adenosine re-uptake in tissue level and can induce adenosine triphosphate (ATP) release from human red cells, which both stimulate vasodilation of in red blood cells.

Conditions

• Non-ST Segment Elevation Myocardial Infarction
• ST Segment Elevation Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Clopidogrel	Clopidogrel 600mg loading
DRUG	Ticagrelor	Ticagrelor 180mg loading

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-10-01
• Completion: 2014-12-01
• First posted: 2014-01-01
• Last updated: 2015-10-01

Locations

1 site across 1 country: South Korea